Enantioselective Crystallization of Hydroxy Cineole Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for separating optically active hydroxy cineole derivatives suffer from low enantiomeric excess and poor yields, often requiring expensive reagents and lacking a predictable basis for crystallization resolution, making them inefficient and economically unfeasible for industrial scale.
Innovation Solution
A method involving enantioselective lixiviation and crystallization using a non-polar solvent to separate optically active hydroxy cineole derivatives, with seeding of supersaturated solutions to enhance enantiomeric excess, allowing for the recycling of racemates and achieving enantiomeric excess of at least 99.5% without compromising yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional crystallization methods are used for separating optically active hydroxy cineole derivatives, then the process can be carried out economically on industrial scale, but the enantiomeric excess obtained is insufficient and yields are poor
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including temperature gradients, solvent composition ratios, and supersaturation levels to achieve both high enantiomeric excess (>99.5% ee) and high yield (>90%). The method transforms the conventional approach by using controlled cooling rates and specific solvent systems (e.g., hexane/ethyl acetate mixtures) to optimize the crystallization process for simultaneous high purity and high recovery.
Solution Approach 2:
The patent employs preliminary action through pre-treatment steps including selective dissolution of the racemate in specific solvent systems before crystallization, and use of seed crystals to initiate enantioselective crystallization. These preliminary steps prepare the system in advance to favor the formation of the desired enantiomer crystals while maintaining high overall recovery, resolving the contradiction between purity and yield.
2Manufacturing precision
If expensive reagents are used for chemical or biological resolution methods, then higher enantiomeric excess can be achieved, but the process becomes economically unfeasible for industrial scale
Solution Approach 1:
The patent replaces expensive chiral reagents or biological catalysts with inexpensive, readily available solvents and simple crystallization conditions. The method uses common solvents like hexane, ethyl acetate, and their mixtures, along with basic temperature control, to achieve >99.5% enantiomeric excess without requiring costly resolving agents, making the process economically viable for industrial production.
Solution Approach 2:
The patent employs self-service by utilizing the inherent physicochemical properties of the hydroxy cineole derivatives themselves to achieve separation. The racemate's own solubility characteristics and crystallization behavior in specific solvent systems are exploited to enable enantioselective crystallization without external chiral auxiliaries, reagents, or catalysts, thereby eliminating the need for expensive resolution chemicals.
3Manufacturing precision
If racemate resolution is performed in late stages of synthesis, then optical purity can be ensured, but precious material is lost during the resolution process
Solution Approach 1:
The patent applies discarding and recovering by efficiently separating the desired enantiomer through crystallization while recovering the mother liquor containing the other enantiomer for potential recycling or conversion. The high yield (>90%) achieved by this method minimizes material loss compared to conventional resolution methods, as the crystallization process allows for recovery and reuse of materials in the mother liquor, thereby reducing overall substance loss while maintaining optical purity.
4Adaptability or versatility
If existing crystallization methods are used without theoretical basis, then experiments can be conducted, but the results are not predictable and must be determined case by case
Solution Approach 1:
The patent establishes predictability by systematically studying and optimizing key crystallization parameters such as solvent composition, temperature, and supersaturation levels for hydroxy cineole derivatives. This creates a reliable methodological framework that can be applied predictably to similar compounds, reducing the need for extensive case-by-case experimental determination while maintaining adaptability to specific molecular structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively separates optically active hydroxy cineole derivatives with high enantiomeric excess, eliminating material loss and enabling efficient, economically viable industrial-scale production, while also allowing for the synthesis of enantiomerically pure 7-oxabicyclo[2.2.1]heptane derivatives.
Implementation Method 1
enantiomer separation by using at least one non-polar solvent enantioselectively by lixiviation and crystallization resolution
Implementation Method 2
A seeding of a supersaturated solution of the racemate with a desired single enantiomer, under controlled conditions increases the enantiomeric excess of the desired enantiomer
Implementation Method 3
A seeding of a supersaturated solution of the racemate with a desired single enantiomer
Data Source
AI summary
The present invention relates to a method for separating an optically active hydroxy cineole derivatives by lixiviation and crystallization and enantiomerically pure optically active hydroxy cineole derivatives of purity greater than 99.5% that have been prepared by this process. The present invention further relates to use of the desired enantiomer having enantiomeric excess of at least 99.5% ee as prepared according to the present invention, for the synthesis of enantiomerically pure 7-oxabicyclo[2.2.1]heptane derivatives.